PMID- 35527653
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220510
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 50
IP  - 3
DP  - 2022
TI  - Systematic review and meta-analysis of probiotics in the treatment of allergic 
      rhinitis.
PG  - 24-37
LID - 10.15586/aei.v50i3.507 [doi]
AB  - BACKGROUND: The purpose of this meta-analysis is to systematically evaluate the 
      efficacy of probiotics on allergic rhinitis (AR). METHODS: Collecting randomized 
      controlled trials (RCTs) with probiotics as intervention measures for AR, two 
      researchers independently screened the literature, extracted the data and 
      evaluated the methodological quality of the included studies, and used RevMan 5.3 
      software for meta-analysis to observe the effects of probiotics on Rhinitis 
      Quality of Life (RQLQ) scores, Rhinitis Total Symptom Scores (RTSS), blood 
      eosinophil count, total and antigen-specific serum immunoglobulin E (IgE) levels 
      by using the fixed- or the random-effects model to calculate the pooled risk for 
      significant heterogeneity. RESULTS: A total of 2708 patients were included in 30 
      RCTs. Meta-analysis results showed that the RQLQ global scores (mean difference 
      [MD] = -9.43; P < 0.00001), RQLQ nasal scores (MD = -1.52; P = 0.03), and RTSS 
      nasal scores (MD = -1.96; P = 0.02) significantly improved in the probiotic group 
      when compared with those in the placebo group. There was no significant 
      difference in blood eosinophil count (MD = -0.09; P=0.82), RQLQ eye scores (MD = 
      -1.45; P = 0.07), RTSS global scores (MD = -2.24; P = 0.26), RTSS eye scores (MD 
      = -0.39; P = 0.31), total and antigen-specific serum IgE levels (MD = -0.04; P = 
      0.7 and MD = -0.08; P = 0.81) between the probiotic and the placebo group. 
      CONCLUSION: Compared with the placebo group, the quality of life and symptoms of 
      patients with AR significantly improved in the probiotic group, thus providing a 
      new potential method for the application of probiotics in AR. However, because of 
      the limited evidence for the current study outcomes, the heterogeneity of 
      research, and the differences in research results, more high-quality studies are 
      needed to in the future.
FAU - Yan, Shuiping
AU  - Yan S
AD  - Academy of Integrative Medicine, Fujian University of Traditional Chinese 
      Medicine, Fuzhou, China.
FAU - Ai, Si
AU  - Ai S
AD  - The Affiliated People's Hospital of Fujian University of Traditional Chinese 
      Medicine, Fuzhou, China.
FAU - Huang, Lizhen
AU  - Huang L
AD  - Shenzhen Hospital of Guangzhou, University of Chinese Medicine, Shenzhen, China.
FAU - Qiu, Caixia
AU  - Qiu C
AD  - The Affiliated People's Hospital of Fujian University of Traditional Chinese 
      Medicine, Fuzhou, China.
FAU - Zhang, Fangting
AU  - Zhang F
AD  - Fuding City Hospital, Fuding, China.
FAU - He, Ningxin
AU  - He N
AD  - Fuqing Traditional Chinese Medicine Hospital, Fuqing, China.
FAU - Zhuang, Xiangli
AU  - Zhuang X
AD  - The Affiliated People's Hospital of Fujian University of Traditional Chinese 
      Medicine, Fuzhou, China; zhuang-xl@qq.com.
FAU - Zheng, Jian
AU  - Zheng J
AD  - The Affiliated People's Hospital of Fujian University of Traditional Chinese 
      Medicine, Fuzhou, China; zhengjian7816@126.com.
AD  - Institute of Pediatrics of Traditional Chinese Medicine, Fujian University of 
      Traditional Chinese Medicine, Fuzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220501
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - Immunoglobulin E
MH  - *Probiotics/therapeutic use
MH  - Quality of Life
MH  - *Rhinitis
MH  - *Rhinitis, Allergic/drug therapy
OTO - NOTNLM
OT  - allergic rhinitis
OT  - meta-analysis
OT  - probiotics
EDAT- 2022/05/10 06:00
MHDA- 2022/05/11 06:00
CRDT- 2022/05/09 03:16
PHST- 2021/09/18 00:00 [received]
PHST- 2021/11/16 00:00 [accepted]
PHST- 2022/05/09 03:16 [entrez]
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
AID - 10.15586/aei.v50i3.507 [doi]
PST - epublish
SO  - Allergol Immunopathol (Madr). 2022 May 1;50(3):24-37. doi: 
      10.15586/aei.v50i3.507. eCollection 2022.